Big Pharma backs clinical trials industry in Quebec

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/dk_photos)
(Image: Getty/dk_photos)

Related tags: Glaxosmithkline, Pfizer, AbbVie, Takeda, Novartis, Merck, Servier, Roche, Clinical trials

Pharma giants including Pfizer, GSK, and Abbvie, renew their financial commitment to the early-stage clinical research in Quebec, Canada.

Catalis Québec is a is a public-private partnership developing tools to support early-stage clinical research. The organization “has the mandate of promoting Quebec's expertise in conducting early-stage clinical trials,”​ said Danika Laberge, general director of Catalis Quebec.

Catalis has partnerships with five Quebec-based health and social service organizations and eight pharmaceutical companies, including GlaxoSmithKline, Pfizer, AbbVie, Takeda, Novartis, Merck, Servier, and Roche, which have invested nearly CAD 1.6m ($1.19m) in the Catalis initiative since 2017.

The pharma companies this week announced renewed financial commitments to Catalis during the 2019 BIO International Convention.

“Catalis Quebec acts as a coordination office by rallying behind the efforts of its partners in order to stimulate private investment and promote excellence in the conduct of phase I, II and II-III clinical trials,”​ explained Laberge.

“Our projects benefit all life science research stakeholders and have positive economic and social impacts for Quebec and Canada,” ​she told us.

Projects announced so far this year include the development of standard operating procedures for ethical reviews of clinical research, an automated performance reporting tool, and a new system to manage and approve multicenter research projects.

Per ClinicalTrials.gov there are more than 1,400 studies currently underway in Canada. Laberge described Quebec as a preferred location “for its medical and scientific expertise, state-of-the-art infrastructure and research-friendly economic and regulatory environment,”​ said Laberge.

“Quebec has everything it needs to meet the growing demand,”​ she added, citing a $10bn investment from the Government of Quebec to modernize its health care facilities.

Said Laberge, “Several institutions have established Phase I clinical research units, which provides an environment conducive to early clinical trials.”

Related topics: Clinical Development, Phase I-II

Related news

Related products

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers

Follow us

Products

View more

Webinars